A Precision Partnership to Beat Cancer | Stories | PerkinElmer
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

A Precision Partnership To Beat Cancer

July 07, 2016

A Precision Partnership to Beat Cancer

Weeks have passed since leaders from PerkinElmer and the Genome Institute of Singapore, a biomedical sciences research institute under Singapore’s Agency for Science, Technology and Research (A*STAR), unveiled the PerkinElmer-GIS Centre for Precision Oncology in Queenstown. 1

Since its late April opening, the new center is already hard at work to integrate the extensive genetics expertise of the GIS staff with PerkinElmer’s globally-recognized imaging and analysis systems that populate the new lab, located in a 7,200 square meter facility aptly named the Genome. 2 Together, the new research platform will evaluate the effectiveness of novel cancer inhibitors using 3D tumor models derived either directly from patients’ primary tumors or patient-derived models. These models will undergo extensive analysis using a comprehensive suite of advanced PerkinElmer imaging systems.  The collaboration is hoped to lead to new clinical therapies in individual cancer care through precision medicine.

“Our collaboration with GIS brings together cutting-edge equipment and services, along with insights from some of the world’s leading cancer researchers,” Brian Kim, President, Life Sciences & Technology, PerkinElmer, says. “PerkinElmer’s integrated solutions empower researchers to reach greater insights for greater outcomes. Combined with GIS’s knowledge and experience, this collaboration has the potential to unlock new doors in the future of applying precision medicine to cancer treatment.”

Professor Ng Huck Hui, Executive Director, GIS, agrees. “We look forward to working closely with PerkinElmer, leveraging our respective strengths, to advance precision oncology and bring our research findings directly to patients.”

Among the PerkinElmer instruments included in the new PerkinElmer-GIS Centre are: the Operetta® High Content Imaging System; Opera Phenix™ High Content Screening System; the FMT® 4000 In Vivo Screening System; the Mantra™ Quantitative Pathology workstation; and the EnSpire® Multimode Plate Reader. PerkinElmer will also provide ongoing technical expertise for advanced, high-throughput, quantitative imaging and analysis.

The PerkinElmer instruments mentioned are for research use only. Not for use in diagnostic procedures.


  1. Anon., “PerkinElmer and Genome Institute of Singapore Open Joint Research Laboratory to Advance Precision Oncology,” PerkinElmer Press Release, April 26, 2016
  2. A*STAR, “The GIS Story,” Genome Institute of Singapore, accessed June 16, 2016. https://www.a-star.edu.sg/gis/

Read More Stories Like This One

Shelf Life: Take Control of Stability Testing

Typically, both drug substance and drug product are tested in at least two different storage conditions: long term ambient storage temperature and accelerated co...

GMP Compliance in QC Labs: It Takes a Village

Meeting standards for Good Manufacturing Practice (GMP) compliance is increasingly difficult for pharma labs. Regulatory bodies around the globe enforce these st...